DIETHYLCARBAMAZINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C10H21N3O
Molecular Weight	199.2932
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCN(CC)C(=O)N1CCN(C)CC1

InChI

InChIKey=RCKMWOKWVGPNJF-UHFFFAOYSA-N

InChI=1S/C10H21N3O/c1-4-12(5-2)10(14)13-8-6-11(3)7-9-13/h4-9H2,1-3H3

HIDE SMILES / InChI

Molecular Formula	C10H21N3O
Molecular Weight	199.2932
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://apps.who.int/medicinedocs/en/d/Jh2922e/3.5.1.html
Curator's Comment: description was created based on several sources, including http://filobase.bicpu.edu.in/banocide.pdf

Diethylcarbamazine is used in humans, dogs and cats for the treatment of parasitic infections, including pulmonary eosinophilia, loiasis, and lymphatic filariasis. The exact mechanism of its action is unknown, however some studies showed the involvment of inducible nitric-oxide synthase and the cyclooxygenase pathway. Although there is no information on whether the drug is marketed in the USA and Europe, it is currently used in India.

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Tropical pulmonary eosinophilia 3 Sources: http://india-pharma.gsk.com/media/701051/banocide-and-banocide-forte.pdf	Curative	Approved 8583	BANOCIDE Approved Use Used for the treatment of individual patients with certain filarial diseases including tropical pulmonary eosinophilia, loiasis, and lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori.
Loiasis 3 Sources: http://india-pharma.gsk.com/media/701051/banocide-and-banocide-forte.pdf	Curative	Approved 8583	BANOCIDE Approved Use Used for the treatment of individual patients with certain filarial diseases including tropical pulmonary eosinophilia, loiasis, and lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori.
Lymphatic filariasis 3 Sources: http://india-pharma.gsk.com/media/701051/banocide-and-banocide-forte.pdf	Curative	Approved 8583	BANOCIDE Approved Use Used for the treatment of individual patients with certain filarial diseases including tropical pulmonary eosinophilia, loiasis, and lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori.

C_max

Value	Dose	Co-administered	Analyte	Population
500 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		DIETHYLCARBAMAZINE serum	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
637 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		DIETHYLCARBAMAZINE serum	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
5840 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		DIETHYLCARBAMAZINE serum	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
7220 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		DIETHYLCARBAMAZINE serum	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
14.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		DIETHYLCARBAMAZINE serum	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
11.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		DIETHYLCARBAMAZINE serum	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED

Doses

Dose	Population	Adverse events
6 mg/kg 1 times / day multiple, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: multiple Dose: 6 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7001687/	unhealthy, 12 to 69 years Health Status: unhealthy Age Group: 12 to 69 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/7001687/	Other AEs: Fever, Pruritus... Other AEs: Fever (63.6%) Pruritus (9.1%) Giddiness (9.1%) Joint ache (9.1%) Sources: https://pubmed.ncbi.nlm.nih.gov/7001687/
2 mg/kg 3 times / day multiple, oral Studied dose Dose: 2 mg/kg, 3 times / day Route: oral Route: multiple Dose: 2 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7001687/	unhealthy, 13 to 46 years Health Status: unhealthy Age Group: 13 to 46 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/7001687/	Other AEs: Fever, Nausea... Other AEs: Fever Nausea (27.3%) Vomiting (18.2%) Abdominal discomfort (9.1%) Sources: https://pubmed.ncbi.nlm.nih.gov/7001687/
50 mg multiple, oral Studied dose Dose: 50 mg Route: oral Route: multiple Dose: 50 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/	unhealthy, 37 years Health Status: unhealthy Age Group: 37 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/	Other AEs: Lymphadenopathy, Papular urticarial eruption... Other AEs: Lymphadenopathy (100%) Papular urticarial eruption (30%) Proteinuria (10%) Visual field constriction (20%) Optic nerve pallor (10%) Corneal opacity (90%) Anterior uveitis (10%) Chorioretinitis (10%) Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/
300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/	unhealthy, 40 years Health Status: unhealthy Age Group: 40 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/	Other AEs: Lymphadenopathy, Papular urticarial eruption... Other AEs: Lymphadenopathy (100%) Papular urticarial eruption (70%) Proteinuria (30%) Visual field constriction (10%) Optic nerve pallor (20%) Corneal opacity (80%) Anterior uveitis (30%) Chorioretinitis (30%) Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/
6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/31641754/	unhealthy, median age 35 years Health Status: unhealthy Age Group: median age 35 years Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/31641754/	Other AEs: Fatigue, Nausea... Other AEs: Fatigue (grade 2, 5%) Nausea (grade 2, 2%) Vomiting (grade 2, 2%) Joint pain (grade 2, 2%) Eye swelling (grade 2, 2%) Rash (grade 2, 2%) Dyspnea (grade 2, 2%) Sources: https://pubmed.ncbi.nlm.nih.gov/31641754/
8 mg/kg 3 times / day multiple, oral Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/	unhealthy Health Status: unhealthy Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/	Other AEs: Fever, Headache... Other AEs: Fever (69%) Headache (65%) Vertigo (57%) Malaise (49%) Chills (45%) Joint pain (40%) Abdominal pain (37%) Chest pain (33%) Nausea (28%) Neck pain (24%) Vomiting (16%) Muscular pain (14%) Lymph node tenderness (38%) Epididymal tenderness (34%) Nodule (15%) Tinnitus (8%) Convulsion (2%) Eruption (<1%) Shock (<1%) Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252	inhibitor 2438	inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2C19 2057 OATP1B1 1079 OATP1B3 961	CYP1A2 1197 CYP2B6 776 P-gp 2052	CYP1A 59

Drug as perpetrator

Target	Modality	Activity
CYP2C19 2141	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDkzNyJ9fQ%3D%3D	no [Activation >10 uM]
CYP1A 122	inducer 1966 Sources: https://pubmed.ncbi.nlm.nih.gov/12451431/	no
CYP1A2 2333	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/29/1/30.short	no
CYP2C9 2497	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/29/1/30.short	no
CYP2D6 2546	inhibitor 4027 Sources: https://link.springer.com/article/10.1007/BF00202169	no
CYP3A4 2633	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/29/1/30.short	no
OATP1B1 1095	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNjk3NjY4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDkzNyJ9fQ%3D%3D	yes [Inhibition 10 uM]
OATP1B3 970	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTIxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDkzNyJ9fQ%3D%3D	yes [Inhibition 10 uM]
CYP2C19 2141	activator 342 Sources: https://dmd.aspetjournals.org/content/29/1/30.short	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP1A2 1197	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/12920490/	likely
CYP2B6 776	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/12920490/	likely
CYP3A4 1946	substrate 4014 Sources: http://smj.medicine.psu.ac.th/index.php/smj/article/view/950	no	no (co-administration study) Comment: Coadministration of refampicin/ketoconazole did not affect the exposure of diethylcarbamazine. Sources: http://smj.medicine.psu.ac.th/index.php/smj/article/view/950
P-gp 2052	substrate 4014 Sources: http://smj.medicine.psu.ac.th/index.php/smj/article/view/950	no	no (co-administration study) Comment: Coadministration of refampicin/ketoconazole did not affect the exposure of diethylcarbamazine. Sources: http://smj.medicine.psu.ac.th/index.php/smj/article/view/950

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA00IFVB	http://www.aablocks.com/goods/Goods/detail?id=AA00IFVB
Aaron Chemicals	AR00IGN3	http://www.aaronchem.com/90-89-1
abcr GmbH	AB357734	http://www.abcr.com/shop/en/AB357734
Achemo Scientific Limited	AC-89305	http://www.achemo.com/search/?Keyword= 90-89-1
AEchem Scientific Corp., USA	AE028779	http://www.aechemsc.com/info_products/AE028779.php
Alichem	490014501	http://www.alichem.com/en/products/90-89-1.html
Angene	AGN-PC-0JK6FF	http://www.angenechemical.com/productshow/AGN-PC-0JK6FF.html
Ark Pharm	AK158485	http://www.arkpharminc.com/products/90-89-1.html
Ark Pharma Scientific Limited	H-012789	http://www.arkpharmtech.com/product/17844.html
Aurora Fine Chemicals LLC	A13.142.491	http://online.aurorafinechemicals.com/info?ID=A13.142.491
Aurum Pharmatech LLC	NE55264	http://www.Aurumpharmatech.com/Product/ProductDetails/NE55264
BLD Pharm	BD23082	http://www.bldpharm.com/products/90-89-1.html
ChemMol	99173714	http://www.chemmol.com/chemmol/99173714.html
Chemspace	CSSB00000693863	https://chem-space.com/CSSB00000693863
Clearsynth	CS-MM-79413	https://www.clearsynth.com/en/CSMM79413.html
Debye Scientific	DB-080764	http://www.debyesci.com/cas_90-89-1.html
eNovation Chemicals	Y0988700	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y0988700
Finetech	FT-0624832	http://www.finetechnology-ind.com/prod/detail/pub/90-89-1.html
Frinton	FR-1031	https://www.frinton.com/search/?filtername=NN-Diethyl-4-methyl-1-piperazinecarboxamide
iChemical	EBD3427	http://www.ichemical.com/chemicals/cas-90-89-1
Lab Network	LN01325414	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01325414
Matrix Scientific	172278	https://www.matrixscientific.com/172278.html
mcule	MCULE-7296820622	https://mcule.com/MCULE-7296820622/
Molcore	MC578639	https://www.molcore.com/product/90-89-1
Parchem	28724	http://www.parchem.com/chemical-supplier-distributor/Diethyl-Carbamazine-Citrate-018724.aspx
R&D Chemicals	FR-1031	http://www.rdchemicals.com/chemicals.php?mode=details&mol_id=2751
Sigma-Aldrich	PH003578_ALDRICH	https://www.sigmaaldrich.com/catalog/product/aldrich/ph003578
Smolecule	S526027	http://www.smolecule.com/products/s526027
THE BioTek	bt-264510	https://www.thebiotek.com/product/inhibitors/bt-264510
Yuhao Chemical	XJ0184	http://www.chemyuhao.com/90-89-1.html
001 Chemical	DY578639	https://www.001chemical.com/chem/90-89-1
3B Scientific (Wuhan) Corp	3B3-061821	http://www.3bsc.com/index/pro_info.php?id=100910

PubMed

Title	Date	PubMed
A brief introduction to the research achievement on the strategy and technical measures for interrupting the transmission of lymphatic filariasis in China.	2001	12572001
Compliance with the mass chemotherapy program for lymphatic filariasis.	2001 Dec	12164029
Lymphatic filariasis in kenya since 1910, and the prospects for its elimination: a review.	2001 Nov	12219966
Mass DEC campaign for filariasis in a hyper endemic district of West Bengal.	2001 Sep	12206039
[Toxocariasis in Poznan region, Poland, in years 1990-2000].	2002	12666581
[Technical measures of filariasis elimination in Tengzhou City].	2002	12568031
Carbamazepine-provoked hepatotoxicity and possible aetiopathological role of glutathione in the events. Retrospective review of old data and call for new investigation.	2002	12298421
Genetic variability of the human filarial parasite, Wuchereria bancrofti in South India.	2002 Apr	11904105
The impact of single-dose diethylcarbamazine treatment of bancroftian filariasis in a low-endemicity setting in Egypt.	2002 Aug	12389947
Modelling the epidemiology, transmission and control of lymphatic filariasis.	2002 Dec	12625928
Use of floating layers of polystyrene beads to control populations of the filaria vector Culex quinquefasciatus.	2002 Dec	12625923
Cost-effectiveness of the use of vector control and mass drug administration, separately or in combination, against lymphatic filariasis.	2002 Dec	12625921
Operational issues in the control of the vectors of Brugia.	2002 Dec	12625920
Progress towards, and challenges for, the elimination of filariasis from Pacific-island communities.	2002 Dec	12625919
Detection of Onchocerca volvulus infection in low prevalence areas: a comparison of three diagnostic methods.	2002 Dec	12553573
Bancroftian filariasis: clinical parasitologic and serologic evaluation after 4 years applying two antifilarial regimens.	2002 Dec	12512817
Major progress toward eliminating lymphatic filariasis.	2002 Dec 5	12466515
Mass treatment to eliminate filariasis in Papua New Guinea.	2002 Dec 5	12466508
Antigenemia at 10 years after diethylcarbamazine treatment of asymptomatic microfilaraemic individuals: marginal conversion to infection-free state.	2002 Feb	11874566
Efficacy of co-administration of albendazole and diethylcarbamazine against geohelminthiases: a study from South India.	2002 Jun	12031078
Mass drug administration to treat lymphatic filariasis.	2002 Jun 1	12057582
Chemotherapeutic approaches to nematodes: current knowledge and outlook.	2002 Mar	11954915
Bacterial endosymbionts of Onchocerca volvulus in the pathogenesis of posttreatment reactions.	2002 Mar 15	11920298
Case 1-2002: Loa loa.	2002 May 30	12037162
Electron microscopic and molecular identification of Wolbachia endosymbionts from Onchocerca lupi: implications for therapy.	2002 May 30	11992713
[Asthenoscopic problems with a subconjunctival worm].	2002 Nov	12515271
Neoplastic change in Onchocerca volvulus and its relation to ivermectin treatment.	2002 Nov	12458827
Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells.	2002 Nov	12451431
Prevalence of diurnally subperiodic bancroftian filariasis among the Nicobarese in Andaman and Nicobar Islands, India: effect of age and gender.	2002 Nov	12390601
Targeting of children in filariasis mass drug administration.	2002 Nov 2	12424026
Case report: intraocular localization of Mansonella perstans in a patient from south Chad.	2002 Nov-Dec	12625144
Red blood cell antioxidant levels in Wuchereria bancrofti infection.	2002 Oct	12706743
Microfilaria in a thyroid nodule which resolved on treatment.	2002 Oct	12405321
Treatment of Brugia timori and Wuchereria bancrofti infections in Indonesia using DEC or a combination of DEC and albendazole: adverse reactions and short-term effects on microfilariae.	2002 Oct	12358626
The pharmacokinetics, safety and tolerability of the co-administration of diethylcarbamazine and albendazole.	2002 Sep	12396323
The influence of the mass administration of diethylcarbamazine, alone or with albendazole, on the prevalence of filarial antigenaemia.	2002 Sep	12396322
The effect of six rounds of single dose mass treatment with diethylcarbamazine or ivermectin on Wuchereria bancrofti infection and its implications for lymphatic filariasis elimination.	2002 Sep	12225508
Efficacy and sustainability of a footcare programme in preventing acute attacks of adenolymphangitis in Brugian filariasis.	2002 Sep	12225507
Statistical issues in the assessment of the evidence for an interaction between factors in epilepsy trials.	2002 Sep 30	12228880
Targeting apoptotic signalling pathway and pro-inflammatory cytokine expression as therapeutic intervention in TPE induced lung damage.	2003	12788054
A comparison of the efficacy of single doses of albendazole, ivermectin, and diethylcarbamazine alone or in combinations against Ascaris and Trichuris spp.	2003	12640474
Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari District, South India.	2003 Apr	12680538
Long-term population migration: an important aspect to be considered during mass drug administration for elimination of lymphatic filariasis.	2003 Apr	12667150
Long-term follow-up of treatment with diethylcarbamazine on anti-filarial IgG4: dosage, compliance, and differential patterns in adults and children.	2003 Jan	12556144
Serum immunoglobulin G4 antibodies to the recombinant antigen, Ll-SXP-1, are highly specific for Loa loa infection.	2003 Jan 1	12508156
Relationships between Wuchereria bancrofti microfilaria counts in human blood and parasite uptake and maturation in Culex pipiens, with observations on the effects of diethylcarbamazine treatment on these parameters.	2003 Mar	12685631
Setaria cervi: in vitro released collagenases and their inhibition by Wuchereria bancrofti infected sera.	2003 Mar	12590669
Strategic options for global lymphatic filariasis elimination.	2003 May	12763424
Ensuring supplies of quality diethylcarbamazine citrate (DEC).	2003 May	12751269
Lymphatic filariasis.	2003 May 16	12808788

Sample Use Guides

In Vivo Use Guide

Lymphatic filariasis: 6 mg/kg daily for 12 days administered orally, preferably in divided doses after meals (W. bancrofti infection); 3-6 mg/kg daily for 6-12 days administered orally, preferably in divided doses after meals (B. malayi and B. timori infections). Tropical pulmonary eosinophilia: a dose of 8 mg/kg daily for 14 days repeated, as necessary, if symptoms return.

Route of Administration: Oral

In Vitro Use Guide

Larvae of nocturnally subperiodic Brugia malayi was inhibited under incubation with diethylcarbamazine at concentration of 10(-5) M.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 08:41:28 GMT 2025` Edited by `admin` on `Wed Apr 02 08:41:28 GMT 2025`
Record UNII	V867Q8X3ZD
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DIETHYLCARBAMAZINE

Official Name

English

CAMIN

Preferred Name

English

N,N-DIETHYL-4-METHYL-1-PIPERAZINECARBOXAMIDE

Systematic Name

English

Diethylcarbamazine [WHO-DD]

Common Name

English

diethylcarbamazine [INN]

Common Name

English

DIETHYLCARBAMAZINE [MI]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QP52AH02